A developer of dendrimer products, Starpharma
(ASX:SPL) has received Australian marketing approval from the Therapeutic Goods of Administration (TGA) for its product, VivaGel, that treats bacterial vaginosis.
Starpharma’s VivaGel is now expected to be available in pharmacies in the new year.
The product developed by Starpharma, will be marketed by Aspen Pharmacare as Fleurstat BV gel, carrying the VivaGel brand.
Aspen will also promote and distribute the product to clinicians and pharmacies in Australia and New Zealand.
Shares in Starpharma
(ASX:SPL) are trading 3.36 per cent higher to $1.39.
